PharmaPoint: Non-Small Cell Lung Cancer – China Drug Forecast and Market Analysis to 2022

London (PRWEB) October 16, 2013

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

GlobalData estimates that branded NSCLC market in China will grow in the forecast period. This increase will be due largely to an increasing aging population; increased use of EGFR and ALK targeted therapies and increased numbers of people covered by private health insurance.

Scope

-Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in China from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting China NSCLC market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in China.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology and Histology 13
3.1.3 NSCLC Biomarkers 14
3.1.4 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 20
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25
4.2 China 27
4.2.1 Diagnosis 27
4.2.2 Clinical Practice 28
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
5.3 Product Profiles – Major Brands, Chemotherapies 33
5.3.1 Alimta (pemetrexed disodium) 33
5.4 Product Profiles – Major Brands, Targeted Therapies 37
5.4.1 Iressa (gefitinib) 37
5.4.2 Tarceva (erlotinib hydrochloride) 42
5.4.3 Xalkori (crizotinib) 48
5.4.4 Avastin (bevacizumab) 52
6 Opportunity and Unmet Need 56
6.1 Overview 56
6.2 Improved Overall Survival and Less Toxicity 57
6.3 Treatments for Patients with Acquired TKI Resistance 58
6.4 Better Treatment Options for Squamous Patients 58
6.5 Preventing Relapse or Recurrence 59
6.6 More Efficacious Second-Line Therapies 59
6.7 Increased Availability of Mutation Testing 60
6.8 More Cost-Effective Therapies 61
6.9 Unmet Needs Gap Analysis 61
7 Pipeline Assessment 65
7.1 Overview 65
7.2 Promising Drugs in Clinical Development 65
7.2.1 nintedanib (BIBF1120) 69
7.2.2 Gilotrif (afatinib) 73
7.2.3 dacomitinib (PF-00299804) 79
7.2.4 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 83
8 Market Outlook 88
8.1 China 88
8.1.1 Forecast 88
8.1.2 Key Events 91
8.1.3 Drivers and Barriers 91
9 Appendix 95
9.1 Bibliography 95
9.2 Abbreviations 107
9.3 Methodology 111
9.4 Forecasting Methodology 111
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 111
9.4.2 Percent Drug-treated Patients 112
9.4.3 Drugs Included in Each Therapeutic Class 112
9.4.4 Launch and Patent Expiry Dates 113
9.4.5 General Pricing Assumptions 114
9.4.6 Individual Drug Assumptions 117
9.4.7 Generic Erosion 121
9.4.8 Pricing of Pipeline Agents 122
9.5 Physicians and Specialists Included in This Study 124
9.6 Survey of Prescribing Physicians 126
9.7 About the Authors 127
9.7.1 Authors 127
9.7.2 Epidemiologists 128
9.7.3 Global Head of Healthcare 129
9.8 About GlobalData 130
9.9 Disclaimer 130
1.1 List of Tables

Table 1: Symptoms of Disease NSCLC 17
Table 2: Treatment Guidelines for NSCLC 19
Table 3: Stage Definitions for NSCLC 21
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 27
Table 5: Leading Treatments for NSCLC 33
Table 6: Product Profile – Alimta (pemetrexed disodium) 35
Table 7: Alimta SWOT Analysis, 2013 37
Table 8: Product Profile – Iressa (gefitinib) 39
Table 9: Iressa SWOT Analysis, 2013 42
Table 10: Product Profile – Tarceva (erlotinib hydrochloride) 44
Table 11: Tarceva SWOT Analysis, 2013 47
Table 12: Product Profile – Xalkori (crizotinib) 49
Table 13: Xalkori SWOT Analysis, 2013 52
Table 14: Product Profile – Avastin (bevacizumab) 53
Table 15: Avastin SWOT Analysis, 2013 55
Table 16: Overall Unmet Needs – Current Level of Attainment 57
Table 17: Clinical Unmet Needs – Gap Analysis, 2013 62
Table 18: Non-Small Cell Lung Cancer – Phase I-II Pipeline, 2013 66
Table 19: NSCLC – Phase III Pipeline, 2013 67
Table 20: NSCLC – Advantages and Disadvantages of Therapeutic Classes 68
Table 21: Product Profile – nintedanib (BIBF-1120) 69
Table 22: nintedanib SWOT Analysis, 2013 73
Table 23: Product Profile – Gilotrif (afatinib) 74
Table 24: Gilotrif SWOT Analysis, 2013 78
Table 25: Product Profile – dacomitinib (PF-00299804) 79
Table 26: dacomitinib SWOT Analysis, 2013 83
Table 27: Product Profile – GSK1572932A (MAGE-A3 immunotherapy) 84
Table 28: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 87
Table 29: Sales Forecasts ($m) for NSCLC in China, 2012-2022 89
Table 30: Key Events Impacting Sales for Disease NSCLC in China, 2012-2022 91
Table 31: NSCLC Market in China – Drivers and Barriers, 2012–2022 91
Table 32: Five Year Prevalence 112
Table 33: Key Launch Dates 113
Table 34: Key Patent Expiries 114
Table 35: Physicians Surveyed by Country 126
1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012–2022 68
Figure 2: Sales for NSCLC in China by Drug, 2012–2022 90

Read the full report:

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_non_small_cell_lung_cancer_china_drug_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information: Sarah Smith Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11237137.htm